Aspen Pharmacare Holdings Limited

JSE:APN Rapport sur les actions

Capitalisation boursière : R104.7b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Aspen Pharmacare Holdings Gestion

Gestion contrôle des critères 4/4

Le PDG Aspen Pharmacare Holdings' est Stephen Saad, nommé en Jan2000, a un mandat de 24.58 ans. La rémunération annuelle totale est ZAR 24.15M, composée du salaire de 38% et des bonus 62%, y compris les actions et options de la société. détient directement 12.84% des actions de la société, d'une valeur de ZAR 13.36B. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 7.4 ans et 5.3 ans.

Informations clés

Stephen Saad

Directeur général

R24.1m

Rémunération totale

Pourcentage du salaire du PDG38.0%
Durée du mandat du directeur général24.6yrs
Propriété du PDG12.8%
Durée moyenne d'occupation des postes de direction7.4yrs
Durée moyenne du mandat des membres du conseil d'administration5.3yrs

Mises à jour récentes de la gestion

Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation Is Looking A Bit Stretched At The Moment

Dec 01
Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation Is Looking A Bit Stretched At The Moment

Shareholders Will Probably Not Have Any Issues With Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation

Dec 02
Shareholders Will Probably Not Have Any Issues With Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation

Recent updates

We Think Aspen Pharmacare Holdings (JSE:APN) Can Stay On Top Of Its Debt

May 08
We Think Aspen Pharmacare Holdings (JSE:APN) Can Stay On Top Of Its Debt

Aspen Pharmacare Holdings Limited's (JSE:APN) P/E Still Appears To Be Reasonable

Mar 05
Aspen Pharmacare Holdings Limited's (JSE:APN) P/E Still Appears To Be Reasonable

Aspen Pharmacare Holdings (JSE:APN) Has A Pretty Healthy Balance Sheet

Dec 22
Aspen Pharmacare Holdings (JSE:APN) Has A Pretty Healthy Balance Sheet

Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation Is Looking A Bit Stretched At The Moment

Dec 01
Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation Is Looking A Bit Stretched At The Moment

Aspen Pharmacare Holdings (JSE:APN) Has A Pretty Healthy Balance Sheet

Mar 31
Aspen Pharmacare Holdings (JSE:APN) Has A Pretty Healthy Balance Sheet

With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Makes An Interesting Case

Jan 11
With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Makes An Interesting Case

These 4 Measures Indicate That Aspen Pharmacare Holdings (JSE:APN) Is Using Debt Reasonably Well

Oct 22
These 4 Measures Indicate That Aspen Pharmacare Holdings (JSE:APN) Is Using Debt Reasonably Well

We Ran A Stock Scan For Earnings Growth And Aspen Pharmacare Holdings (JSE:APN) Passed With Ease

Oct 06
We Ran A Stock Scan For Earnings Growth And Aspen Pharmacare Holdings (JSE:APN) Passed With Ease

Aspen Pharmacare Holdings' (JSE:APN) Upcoming Dividend Will Be Larger Than Last Year's

Sep 21
Aspen Pharmacare Holdings' (JSE:APN) Upcoming Dividend Will Be Larger Than Last Year's

Aspen Pharmacare Holdings Limited (JSE:APN) Analysts Just Cut Their EPS Forecasts Substantially

Sep 08
Aspen Pharmacare Holdings Limited (JSE:APN) Analysts Just Cut Their EPS Forecasts Substantially

Aspen Pharmacare Holdings (JSE:APN) Is Increasing Its Dividend To ZAR3.26

Sep 07
Aspen Pharmacare Holdings (JSE:APN) Is Increasing Its Dividend To ZAR3.26

Here's Why We Think Aspen Pharmacare Holdings (JSE:APN) Might Deserve Your Attention Today

Jun 15
Here's Why We Think Aspen Pharmacare Holdings (JSE:APN) Might Deserve Your Attention Today

Aspen Pharmacare Holdings (JSE:APN) Seems To Use Debt Quite Sensibly

Apr 02
Aspen Pharmacare Holdings (JSE:APN) Seems To Use Debt Quite Sensibly

With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Is Interesting

Mar 16
With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Is Interesting

An Intrinsic Calculation For Aspen Pharmacare Holdings Limited (JSE:APN) Suggests It's 33% Undervalued

Mar 02
An Intrinsic Calculation For Aspen Pharmacare Holdings Limited (JSE:APN) Suggests It's 33% Undervalued

Is Aspen Pharmacare Holdings (JSE:APN) A Risky Investment?

Dec 23
Is Aspen Pharmacare Holdings (JSE:APN) A Risky Investment?

Shareholders Will Probably Not Have Any Issues With Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation

Dec 02
Shareholders Will Probably Not Have Any Issues With Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation

We Think Aspen Pharmacare Holdings' (JSE:APN) Robust Earnings Are Conservative

Oct 11
We Think Aspen Pharmacare Holdings' (JSE:APN) Robust Earnings Are Conservative

After Leaping 42% Aspen Pharmacare Holdings Limited (JSE:APN) Shares Are Not Flying Under The Radar

Sep 30
After Leaping 42% Aspen Pharmacare Holdings Limited (JSE:APN) Shares Are Not Flying Under The Radar

Aspen Pharmacare Holdings Limited (JSE:APN) Looks Just Right With A 42% Price Jump

Sep 30
Aspen Pharmacare Holdings Limited (JSE:APN) Looks Just Right With A 42% Price Jump

Analyse de la rémunération des PDG

Comment la rémunération de Stephen Saad a-t-elle évolué par rapport aux bénéfices de Aspen Pharmacare Holdings?
DateRémunération totaleSalaireBénéfices de l'entreprise
Dec 31 2023n/an/a

R5b

Sep 30 2023n/an/a

R5b

Jun 30 2023R24mR9m

R5b

Mar 31 2023n/an/a

R6b

Dec 31 2022n/an/a

R6b

Sep 30 2022n/an/a

R6b

Jun 30 2022R23mR9m

R6b

Mar 31 2022n/an/a

R6b

Dec 31 2021n/an/a

R6b

Sep 30 2021n/an/a

R5b

Jun 30 2021R24mR8m

R5b

Mar 31 2021n/an/a

R4b

Dec 31 2020n/an/a

R4b

Sep 30 2020n/an/a

R4b

Jun 30 2020R23mR8m

R3b

Mar 31 2020n/an/a

R3b

Dec 31 2019n/an/a

R870m

Sep 30 2019n/an/a

R1b

Jun 30 2019R14mR8m

R2b

Mar 31 2019n/an/a

R3b

Dec 31 2018n/an/a

R5b

Sep 30 2018n/an/a

R5b

Jun 30 2018R17mR7m

R6b

Rémunération vs marché: La rémunération totale de Stephen ($USD 1.35M ) est dans la moyenne des entreprises de taille similaire sur le marché ZA ($USD 1.72M ).

Rémunération et revenus: La rémunération de Stephen a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.


PDG

Stephen Saad (60 yo)

24.6yrs

Titularisation

R24,149,000

Compensation

Mr. Stephen Bradley Saad, BCom, CA(SA), serves as the Group Chief Executive Officer of Aspen Pharmacare Canada Inc. Mr. Stephen has been the Group Chief Executive Officer of Aspen Pharmacare Holdings Limit...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Stephen Saad
Group CEO & Executive Director24.6yrsR24.15m12.84%
ZAR 13.4b
Sean Capazorio
Group CFO & Executive Director25.6yrsR15.55mpas de données
Lorraine Hill
Group Chief Operations Officer & Responsible Pharmacist10.8yrsR16.59mpas de données
Michael Attridge
Group Chief Advisor2.6yrsR12.62m4.31%
ZAR 4.5b
Reginald Haman
Group Chief Corporate Services Officer & Executive Directorless than a yearR14.21mpas de données
Zizipho Mmango
Group Chief Strategic Development Officer4.3yrsR13.87mpas de données
Sibongakonke Nkosi
Investor Relations Managerno datapas de donnéespas de données
Trevor Ziman
Regional Chief Executive Officer of Asia Pacific10.6yrspas de donnéespas de données
Samer Kassem
Chief Executive Officer of Aspen Global Incorporated7.4yrspas de donnéespas de données
Raeesa Khan
Group Company Secretaryless than a yearpas de donnéespas de données
Luresha Chetty
Corporate Affairs & Investor Relations Executiveno datapas de donnéespas de données

7.4yrs

Durée moyenne de l'emploi

54.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de APN est chevronnée et expérimentée (ancienneté moyenne 7.4 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Stephen Saad
Group CEO & Executive Director25.6yrsR24.15m12.84%
ZAR 13.4b
Sean Capazorio
Group CFO & Executive Director2.6yrsR15.55mpas de données
Reginald Haman
Group Chief Corporate Services Officer & Executive Directorless than a yearR14.21mpas de données
Ben Kruger
Lead Independent Non-Executive Director5.3yrsR932.00kpas de données
Christopher Mortimer
Non-Executive Director25.6yrsR465.00kpas de données
Kuseni Dlamini
Independent Non-Executive Chairman12.3yrsR1.41mpas de données
Yvonne Muthien
Independent Non-Executive Director2.7yrsR548.00kpas de données
David Redfern
Non-Executive Director9.5yrsR364.00kpas de données
Linda de Beer
Independent Non-Executive Director6.1yrsR958.00kpas de données
Neo Dongwana
Independent Non-Executive Directorless than a yearpas de donnéespas de données
Themba Mkhwanazi
Independent Non-Executive Director5.3yrsR448.00kpas de données

5.3yrs

Durée moyenne de l'emploi

57yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de APN sont considérés comme expérimentés (ancienneté moyenne 5.3 ans).